Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) Following Raised Guidance

Benchmark analyst Robert Wasserman reiterated a Buy rating and $75.00 price target on Halozyme Therapeutics (NASDAQ: HALO).

The analyst commented, "Halozyme Therapeutics increased financial guidance for both 2025 and 2026 recently, fueled by year-end license agreements and stronger royalty revenues in 4Q25. Recent contract signings with Takeda, Merus and Skye for core Enhanze drug delivery technology as well as new agreements for small-volume and high-volume auto-injector deployments highlight the guidance boost. For upcoming 4Q25E, we are raising our estimates to revenues of $444.3 million (from $395.0 million), a 49% year-over-year increase, and our adjusted EPS forecast to $2.20 from $1.93. We are also initiating estimates for 2026E, including revenues of $1.74 billion, a 25% increase from 2025E, and adjusted EPS of $8.05. We are maintaining our Buy rating and $75 price target for HALO on the recent positive guidance."

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $74.45 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Full Circle Lithium closes $5.14M private placement
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery